Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (participant self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (informant report of participant) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Self‐efficacy · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Mood: depression (participant self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
QoL · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Quality of life: psychological (care partner self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Intervention not reported
Component · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Varenicline · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in varenicline (low certainty).
1 finding from 1 review
Intervention not reported
Cytisine · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in cytisine (low certainty).
1 finding from 1 review
Intervention not reported
Nicotine patch · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in nicotine patch (low certainty).
1 finding from 1 review
Intervention not reported
Fast‐acting NRT (nicotine other) · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in fast‐acting NRT (nicotine other) (low certainty).
1 finding from 1 review
Intervention not reported
Nicotine EC · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in nicotine EC (low certainty).
1 finding from 1 review
Intervention not reported
Non‐nicotine/placebo EC · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Bupropion · adults (aged ≥ 18 years) who smoked cigarettes Components: components of pharmacological and e‐cigarette (EC) interventions for smoking…
The intervention showed no clear difference in bupropion (moderate certainty).
1 finding from 1 review